The French Gut-colo

NCT ID: NCT06174233

Last Updated: 2025-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-26

Study Completion Date

2028-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer (CRC) is the second most common type of cancer worldwide. The European Union recommends national CRC screening for people aged between 50 and 74. Generally, an immunological test called FIT (Fecal Immunochemical Test), based on the quantitative detection of human haemoglobin, is performed on a stool sample. If the haemoglobin level is above the recommended threshold, a colonoscopy is recommended to detect colorectal lesions. Recent studies have identified potential microbiota signatures associated with colon cancer. In this study, we will analyze the microbiota of a population aged 50 to 75 years undergoing colonoscopy as part of routine care in order to confirm the presence of microbiota signatures associated with the presence of adenomas, advanced adenomas and CRC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many CRC risk factors, such as obesity, low physical activity, a diet low in fibre and high in fat and red meat, and chronic inflammation of the gastrointestinal tract, are known to interact with the intestinal microbiota. Recent studies have identified microbiota signatures associated with colon cancer. These CRC signatures could be used as a solid basis for future screening tests.

This study is an ancillary study of "Le French Gut" study (NCT05758961), a national contribution aiming to collect 100,000 faecal samples and associated nutritional and clinical data. Here, the aim is to identify microbiota profiles associated with the presence of adenomas, advanced adenomas and colorectal cancer (CRC), which would make it possible to recommend follow-up colonoscopies in a more targeted way than the current screening method. The study involves 2,500 patients aged between 50 and 75 who were due to undergo colonoscopy as part of their routine care. Patients recruited in this way will take part in the main "Le French Gut" study, will undergo a colonoscopy as part of their routine care and will complete 2 specific questionnaires relating to their personal and family history as well as their dietary habits in order to assess the risk factors for colorectal cancer as accurately as possible. The FIT test will be carried out as part of routine care with home sampling at the same time as stool sampling using the stool collection kit from the "French Gut" study (same stool sample).

Metagenomic fecal analysis will be coupled with a federated artificial intelligence tool incorporating data collected as part of the French Gut study and specific parameters describing the level of CRC risk. The diagnostic value of the signatures will be compared with that of the FIT test currently used for CRC screening.The ultimate aim is to develop more accurate, non-invasive ways of predicting CRC risk, based on a non-invasive fecal swab that can be taken at home.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients Aged 50-75 and Requiring Colonoscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between the ages of 50 and 75
* Requiring colonoscopy
* Able to provide a faecal sample and to perform a FIT test prior to colonoscopy
* Without known inflammatory bowel disease (chronic inflammatory bowel disease (IBD), chronic ulcerative colitis (CUC) and Crohn's disease (CD))
* No medical condition that, in the opinion of the investigator, should preclude inclusion in the study
* Not having participated in any other clinical research study in which an investigational drug has been administered within 60 days prior to and including the date of informed consent or is likely to be administered during the period of colonoscopy
* Participation agreement signed electronically

Exclusion Criteria

* Persons not living in France (declaratory);
* Persons subject to a protective measure, in particular guardianship or trusteeship, or unable to express their consent (declarative);
* Persons who have had a colectomy (declaratory);
* Person with a digestive stoma (declaration);
* Person who did not sign the consent form;
* Person who did not answer the entry questionnaire;
* Person who did not send a compliant stool sample;
* Antibiotics taken in the 3 months prior to inclusion (self-report);
* Person aged under 50 or over 75.
Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role collaborator

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ROBERT BENAMOUZIG, Pr

Role: PRINCIPAL_INVESTIGATOR

APHP

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Avicenne, Centre de Recherche sur Volontaire

Bobigny, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ROBERT BENAMOUZIG, Pr

Role: CONTACT

00148955434

MOURAD BENALLAOUA, PhD

Role: CONTACT

0033148955024

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Robert BENAMOUZIG, Pr

Role: primary

Mourad BENALLAOUA

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A01941-44

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.